Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Adial Pharmaceuticals ( (ADIL) ) has provided an announcement.
Adial Pharmaceuticals has updated its corporate presentation, highlighting the development of AD04, a genetically targeted precision medication for treating Alcohol Use Disorder (AUD). The medication shows promise by significantly reducing heavy drinking days in patients with specific genotypes, addressing the large unmet medical need in the AUD market, which is characterized by a lack of effective treatments and substantial social and economic costs.
More about Adial Pharmaceuticals
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addictions and other unmet medical needs.
YTD Price Performance: 0.94%
Average Trading Volume: 180,826
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.98M
For an in-depth examination of ADIL stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- FuboTV (NYSE:FUBO) Lawsuit Faces New Challenge from DirecTV
- Tesla’s (NASDAQ:TSLA) Elon Musk Reveals AI Training Has Reached Its Limits
- Mario Gabelli Comes Back for Files in the Paramount (NASDAQ:PARA) Merger
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
